Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease |
| |
Authors: | Chris Vriend MSc Anna H. Nordbeck BSc Jan Booij MD PhD Ysbrand D. van der Werf PhD Tommy Pattij PhD Pieter Voorn PhD Pieter Raijmakers MD Elisabeth M.J. Foncke MD PhD Elsmarieke van de Giessen MD PhD Henk W. Berendse MD PhD Odile A. van den Heuvel MD PhD |
| |
Affiliation: | 1. Department of Psychiatry, VU University Medical Center, , Amsterdam, The Netherlands;2. Department of Anatomy & Neurosciences, VU University Medical Center, , Amsterdam, The Netherlands;3. Neuroscience Campus Amsterdam, VU/VUmc, , Amsterdam, The Netherlands;4. Department of Nuclear Medicine, Academic Medical Center, , Amsterdam, The Netherlands;5. Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, , Amsterdam, The Netherlands;6. Department of Radiology & Nuclear Medicine, VU University Medical Center (VUmc), , Amsterdam, The Netherlands;7. Department of Neurology, VU University Medical Center, , Amsterdam, The Netherlands |
| |
Abstract: | Impulse control disorders (ICD) are relatively common in Parkinson's disease (PD) and generally are regarded as adverse effects of dopamine replacement therapy, although certain demographic and clinical risk factors are also involved. Previous single‐photon emission computed tomography (SPECT) studies showed reduced ventral striatal dopamine transporter binding in Parkinson patients with ICD compared with patients without. Nevertheless, these studies were performed in patients with preexisting impulse control impairments, which impedes clear‐cut interpretation of these findings. We retrospectively procured follow‐up data from 31 medication‐naïve PD patients who underwent dopamine transporter SPECT imaging at baseline and were subsequently treated with dopamine replacement therapy. We used questionnaires and a telephone interview to assess medication status and ICD symptom development during the follow‐up period (31.5 ± 12.0 months). Eleven patients developed ICD symptoms during the follow‐up period, eight of which were taking dopamine agonists. The PD patients with ICD symptoms at follow‐up had higher baseline depressive scores and lower baseline dopamine transporter availability in the right ventral striatum, anterior‐dorsal striatum, and posterior putamen compared with PD patients without ICD symptoms. No baseline between‐group differences in age and disease stage or duration were found. The ICD symptom severity correlated negatively with baseline dopamine transporter availability in the right ventral and anterior‐dorsal striatum. The results of this preliminary study show that reduced striatal dopamine transporter availability predates the development of ICD symptoms after dopamine replacement therapy and may constitute a neurobiological risk factor related to a lower premorbid dopamine transporter availability or a more pronounced dopamine denervation in PD patients susceptible to ICD. © 2014 International Parkinson and Movement Disorder Society |
| |
Keywords: | neuropsychiatry impulse control Parkinson's disease dopamine replacement therapy dopamine transporter |
|
|